Strides Shasun Gets USFDA Nod for Cyproheptadine Hydrochloride Tablets | CORPORATE ETHOS

Strides Shasun Gets USFDA Nod for Cyproheptadine Hydrochloride Tablets

By: | April 12, 2018
Strides Shasun

Apr 12: Bengaluru-headquartered drug maker Strides Shasun Ltd on Thursday announced that its wholly owned subsidiary Strides Pharma Global Pte. Ltd has received approval for its Cyproheptadine Hydrochloride Tablets USP, 4 mg from the United States Food & Drug Administration (USFDA).

According to the company, Cyproheptadine Hydrochloride Tablets is a generic version of Periactin Tablets of us-based Merck & Co. Inc.

“Cyproheptadine Hydrochloride Tablets is an antihistamine used to relieve allergy symptoms such as watery eyes, runny nose, sneezing, hives, and itching,” it said.

According to IQVIA data, the US market for Cyproheptadine Hydrochloride Tablets USP, 4 mg is approximately $20 Million. The product will be manufactured at the company’s oral dosage facility at Bengaluru and will be marketed by Strides Pharma Inc. in the US Market, the company added.

The company has 74 cumulative ANDA filings with USFDA of which 46 ANDAs have been approved as of date and 28 are pending approval.

Strides Shasun shares were trading at Rs 642, up 0.02% from the previous closing of Rs 641.85, on BSE at 12.39 pm today.